184: Phase I Study of Bortezomib, (BTZ) followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL)

✍ Scribed by M. Alsina; T. Alekshun; C. McIsaac-Simonelli; M. Kharfan-Dabaja; W. Dalton; B. Djulbegovic; H. Fernandez; D.M. Sullivan; E. Ayala; T. Field; D. Garrett; W.E. Janssen; B. Maddox; L.E. Perez; D. Kettner; J. Perkins; J. Raychaudhuri; C.H. Anasetti

• Book ID: 116280012
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 52 KB
• Volume: 14
• Category: Article
• ISSN: 1083-8791
• DOI: 10.1016/j.bbmt.2007.12.193